Suspected Herbal Injection Complies With National Standards
This article was originally published in PharmAsia News
Executive Summary
According to Shanxi FDA, Shanxi Taihang Pharmaceutical-produced Yinzhihuang herbal medicine has been examined and proven to comply with China's national drug standards. The herbal medicine caused adverse reactions in four newborn babies in October 2008, resulting in one death (PharmAsia News, Oct. 27, 2008). Subsequently, experts appointed by the state and provincial FDA inspected the company's GMP implementation. In addition, the National Institute for the Control of Pharmaceutical and Biological Products and Shanxi Institute for Drug Control each tested the suspected batch and the results conformed to the national standards. A Shanxi Taihang insider says the company has announced the testing report on its website but resumption ofYinzhihuang sales will depend on the decision of the authorities. (Click here for more - Chinese Language)